Background: Carcinoma lung carries poor prognosis and is the leading cause of death among all malignancies. In developing countries like India, two-third of patients present with advanced stage of disease, where survival is dismal. Hence a retrospective study was planned to be conducted to observe the clinicopathological profile of patients presenting with metastatic lung carcinoma and to analyse the treatment response and survival in these cases. Method: A retrospective analysis was done from hospital files of patients with metastatic carcinoma lung presenting to our hospital from January 2015 to April 2018. Result: Out of 55 patients of metastatic lung carcinoma ,36(65%) were male and 19(35%) were female. Majority of the patients were of elderly age group >60yrs i.e. 47%(36patients),followed by 40-60yrs age group i.e. 31%(17 patients).Considering laterality of primary malignancy, right lung was more commonly affected than left lung(60% vs 40%).Histopathologically adenocarcinoma was the most common variety encountered(85.45%,47 patients) followed by squamous cell variety(0.9%,5 patients).Among 47 patients of adenocarcinoma variety,20 patients(42.5%)have EGFR mutations, whereas 27 patients(57.5%) were EGFR nonmutated. The pattern of metastases shows single organ metastasis in 19 patients (34.5%) and multiple organ metastases in 36 patients(65.5%). Overall bone was the most common site (25 patients) of metastases whereas brain was the most common single organ metastasis site. The follow-up period ranged from 2months to 40 months(median follow-up period-7mnths).One year and two year overall survival was 30% and 10.9% respectively. Subgroup analysis between patients who have received Tyrosine Kinase Inhibitors(TKI)±chemotherapy group and those who have received chemotherapy only group showed median overall survival of 19 months vs 6mnths respectively. Conclusion: In spite of increased awareness, incidence of metastatic lung carcinoma is still high. Adenocarcinoma is the most common histopathological variety. Bone contralateral lung and brain were the common organs involved by metastases. EGFR mutation status should be assessed in all cases of adenocarcinoma lung. Adding TKI in EGFR mutated cases has shown increased survival in our study. Larger sample size and longer follow-up period can further validify the results. Keywords: metastatic, lung, carcinoma Background: Response to PD-1 checkpoint inhibitors in NSCLC is associated with PD-L1 expression. One hypothesis is that high PD-L1 expression may correlate with tumour mutational load, the latter reflecting past tobacco exposure. Method: We examined PD-L1 expression by tumour proportion score (TPS) in patients with advanced NSCLC and correlated this with the subjects' smoking history. Number of pack-years was estimated by the same individual during the initial consultation. Demographic characteristics, performance status(PS), stage, histology were obtained from the electronic patient records. PD-L1 testing was performed using the Dako PD-L1 IHC 22C3 pharmDx test in all but 3 cases where the SP263 Roche antibody was used. We compared pack-years and smoking status of subjects with PD-L1 negative(TPS<1%), weakly-positive (TPS1-49%) and strongly positive (TPS50%) NSCLC. Result: Between 12/2016-3/2018, 54 biopsy specimens from 52 patients with advanced NSCLC were tested for PD-L1 expression at UHB. In 5 biopsies, material was not tested, as unsuitable in 4(<100 tumour cells present) and testing was cancelled in 1 patient who declined treatment. For the remaining 47 biopsies patient characteristics were: Median age 70 (43-82), male/female 26/21, PS 0/ 1/2/3-4 was 10/26/8/3, stage IIIA/IIIB/IV 3/18/26, histology adenoca/squamous/mixed 33/11/3. Median pack-years in PD-L1 negative 30(0-60), PD-L1 weakly positive 35(0-80), PD-L1 strongly positive 33(0-100); current+former smoker/never smoker numbers: PD-L1 negative 14/3(82.4%/17.6%), PD-L1 weakly positive 11/1(91.7%/ 8.3%), PD-L1 strongly positive 15/3(83.3%/16.7%). Strong/weak PD-
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